{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:32:28Z","timestamp":1792099948783,"version":"4.4.0"},"reference-count":14,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"National Institutes of Health\/National Institute of Arthritis and Musculoskeletal and Skin Diseases","award":["K08AR0691110"],"award-info":[{"award-number":["K08AR0691110"]}]},{"name":"Columbia Skin Disease Research Center","award":["NIAMS P30AR044535"],"award-info":[{"award-number":["NIAMS P30AR044535"]}]}],"content-domain":{"domain":["jidonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Dermatology"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.jid.2018.01.032","type":"journal-article","created":{"date-parts":[[2018,2,13]],"date-time":"2018-02-13T22:30:43Z","timestamp":1518561043000},"page":"1539-1545","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":169,"title":["An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis"],"prefix":"10.1016","volume":"138","author":[{"given":"A.","family":"Jabbari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Sansaricq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Cerise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.C.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Bitterman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Ulerio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Borbon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Clynes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.M.","family":"Christiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Mackay-Wiggan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jid.2018.01.032_bib1","first-page":"997","article-title":"The Dermatology Life Quality Index 1994\u20132007: a comprehensive review of validation data and clinical results","volume":"159","author":"Basra","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2018.01.032_bib2","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.cell.2014.09.021","article-title":"Identification of causal genetic drivers of human disease through systems-level analysis of regulatory networks","volume":"159","author":"Chen","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.jid.2018.01.032_bib3","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/0010-440X(91)90045-E","article-title":"Lifetime prevalence of psychiatric disorders in patients with alopecia areata","volume":"32","author":"Colon","year":"1991","journal-title":"Compr Psychiatry"},{"key":"10.1016\/j.jid.2018.01.032_bib4","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/exd.13060","article-title":"Treatment of an alopecia areata patient with tofacitinib results in regrowth of hair and changes in serum and skin biomarkers","volume":"25","author":"Jabbari","year":"2016","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jid.2018.01.032_bib5","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1002\/art.34329","article-title":"The jak inhibitor tofacitinib regulates synovitis through inhibition of interferon-gamma and interleukin-17 production by human CD4+ T cells","volume":"64","author":"Keisuke","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jid.2018.01.032_bib6","first-page":"e89776","article-title":"Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata","volume":"22","author":"Kennedy","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.jid.2018.01.032_bib7","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jaad.2016.09.007","article-title":"Tofacitinib for the treatment of severe alopecia areata and variants: a study of 90 patients","volume":"76","author":"Liu","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"suppl 1","key":"10.1016\/j.jid.2018.01.032_bib8","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1186\/1471-2105-7-S1-S7","article-title":"ARACNE: an algorithm for the reconstruction of gene regulatory networks in a mammalian cellular context","volume":"7","author":"Margolin","year":"2006","journal-title":"BMC Bioinform"},{"issue":"suppl","key":"10.1016\/j.jid.2018.01.032_bib9","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1016\/j.jaad.2006.02.045","article-title":"Alopecia in the United States: outpatient utilization and common prescribing patterns","volume":"57","author":"McMichael","year":"2007","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2018.01.032_bib10","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.jaad.2003.09.032","article-title":"Alopecia areata investigational assessment guidelines\u2014Part II. National Alopecia Areata Foundation","volume":"51","author":"Olsen","year":"2004","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2018.01.032_bib11","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1529-8019.2011.01411.x","article-title":"The genetics of alopecia areata: what's new and how will it help our patients?","volume":"24","author":"Petukhova","year":"2011","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jid.2018.01.032_bib12","doi-asserted-by":"crossref","first-page":"628","DOI":"10.4065\/70.7.628","article-title":"Incidence of alopecia areata in Olmsted County, Minnesota, 1975 through 1989","volume":"70","author":"Safavi","year":"1995","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jid.2018.01.032_bib13","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrrheum.2015.167","article-title":"Type I\/II cytokines, JAKs, and new strategies for treating autoimmune diseases","volume":"12","author":"Schwartz","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.jid.2018.01.032_bib14","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/nm.3645","article-title":"Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition","volume":"20","author":"Xing","year":"2014","journal-title":"Nat Med"}],"container-title":["Journal of Investigative Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X18301179?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X18301179?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T01:02:40Z","timestamp":1561942960000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022202X18301179"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":14,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["S0022202X18301179"],"URL":"https:\/\/doi.org\/10.1016\/j.jid.2018.01.032","relation":{},"ISSN":["0022-202X"],"issn-type":[{"value":"0022-202X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis","name":"articletitle","label":"Article Title"},{"value":"Journal of Investigative Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jid.2018.01.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}]}}